Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CKD-bioMatch biomarker-targeted treatment optimization trial in chronic kidney disease
2023-507449-27-01Phase 4Authorised
- Sponsor
- Steno Diabetes Center Copenhagen
- Start
- Jun 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Countries
- 6
01
Overview
Phase 4, randomised, open-label trial of dapagliflozin, finerenone and semaglutide in chronic kidney disease (CKD) (2 arms), sponsored by Steno Diabetes Center Copenhagen. Primary endpoint: Chronic eGFR slope. Planned start Jun 2025; status: authorised.
02
Drugs
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2023-507449-27-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507449-27-01.